Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Dec 13, 2022
Product Development
Dec. 12 Quick Takes: Setbacks at ASH for Adicet and Lava
Plus: Updates from Magenta, CSL, Hemgenix, Affimed, Kymera and more
BioCentury | Dec 7, 2022
Product Development
ASH22 could be IL-18’s watershed moment
CAR T data at ASH could trigger more development in one of oncology’s less crowded cytokine spaces
BioCentury | Nov 12, 2022
Product Development
Modalities merge into new platforms at SITC 2022
Meeting highlights new platforms combining pieces of cell therapy, bispecific, oncolytic virus and cytokine peptide technologies
BioCentury | Nov 4, 2022
Deals
Nov. 4 Quick Takes: Bayer returns rights to Ionis’ antithrombotic
Plus Vicore gains on IPF data and updates from Acrivon, BioAtla, Novadip and more
BioCentury | Nov 4, 2022
Regulation
Nov. 3 Quick Takes: FDA delay could shorten Apellis’ lead in geographic atrophy
Plus NextCure abandons SIGLEC15 and updates from Emalex, Moderna, Aurinia, Affimed, Artiva and more
BioCentury | May 20, 2022
Product Development
Next-gen NK cell enhancements in the clinic
Companies are turning to tumor targeting, IL-15 expression and alternate cell sourcing to boost the potency and longevity of NK cell therapies
BioCentury | May 3, 2022
Deals
Gilead’s $300M deal with Dragonfly builds on 2022’s NK cell momentum
Dragonfly attracts Gilead as fourth big biopharma partner
BioCentury | Apr 22, 2022
Finance
Affimed shares the reasons behind its raise
A case study of raising follow-on capital in a bear market
BioCentury | Apr 12, 2022
Product Development
AACR Quick Takes: Affimed impresses with NK cell/bispecific antibody combination
Plus: Bicycle’s tox problem, updates from IO Biotech, Innovent
BioCentury | Nov 22, 2021
Product Development
Affimed’s NK cell engager impresses on response rates
Investors still awaiting durability data
Items per page:
1 - 10 of 44